Poly (Lactic-co-Glycolic Acid) Nanoparticles and Nanoliposomes for Protein Delivery in Targeted Therapy: A Comparative In Vitro Study

Atanasio, Giulia De Negri; Ferrari, Pier Francesco; Campardelli, Roberta; Perego, Patrizia; Palombo, Domenico

doi:10.3390/polym12112566

Cited by 16 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA is an ideal carrier because of its stability, low toxicity, controllable biodegradation and good biocompatibility. 20 Therefore, the double emulsion solvent evaporation method 21 was used to prepare TB@PLGA NPs ( Figure S1 ) to prevent the aggregation of TB. Different volume ratios of the TB and PLGA solutions were investigated to optimize the preparation conditions.…”

Section: Resultsmentioning

confidence: 99%

TB@PLGA Nanoparticles for Photodynamic/Photothermal Combined Cancer Therapy with Single Near-Infrared Irradiation

Yang¹,

Tang²,

Liu³

et al. 2021

IJN

View full text Add to dashboard Cite

Background: Phototherapy has significant potential as an effective treatment for cancer. However, the application of a multifunctional nanoplatform for photodynamic therapy (PDT) and photothermal therapy (PTT) at a single excitation wavelength remains a challenge. Materials and Methods: The double emulsion solvent evaporation method was used to prepare toluidine blue@poly lactic-co-glycolic acid (TB@PLGA) nanoparticles (NPs). The biocompatibility of TB@PLGA NPs was evaluated, and a 660 nm luminescence was used as the light source. The photothermal effect, photothermal stability, and singlet oxygen yield of NPs in an aqueous solution verified the feasibility of NPs as a PTT/PDT synergistic therapy drug. Results: TB@PLGA NPs were successfully prepared and characterized. In vitro experiments demonstrated that TB@PLGA NPs can cause massive necrosis of tumor cells and induce apoptosis through a photodynamic mechanism under 660 nm laser irradiation. The TB@PLGA NPs also achieved optimal tumor inhibition effect in vivo. Conclusion:The TB@PLGA NPs prepared in this study were applied as a dual-mode phototherapeutic agent under single laser irradiation. Both in vitro and in vivo experiments demonstrated the good potential of PTT/PDT for tumor inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

TB@PLGA Nanoparticles for Photodynamic/Photothermal Combined Cancer Therapy with Single Near-Infrared Irradiation

Yang¹,

Tang²,

Liu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Both hydrophobic and hydrophilic molecules can be loaded in PLGA nanoparticles [ 201 ]. For example, bovine serum albumin, a hydrophilic serum protein, was encapsulated with high efficiency using PLGA nanoparticles [ 202 , 203 ]; lysozyme and human pigment epithelium-derived factor beta 1 separately encapsulated in PLGA nanoparticles provided sustained release across 30 days [ 204 ]; in vitro sustained release of the antiangiogenic pigment epithelium-derived factor from PLGA nanoparticles was obtained over 40 days with 70% release within 10 days [ 205 ]. The vitreous concentration of bevacizumab was above 500 ng/mL for up to 8 weeks after intravitreal injection of PLGA nanoparticles in rabbits [ 206 ].…”

Section: Formulation Approachesmentioning

confidence: 99%

Ocular Delivery of Therapeutic Proteins: A Review

2023

View full text Add to dashboard Cite

Therapeutic proteins, including monoclonal antibodies, single chain variable fragment (ScFv), crystallizable fragment (Fc), and fragment antigen binding (Fab), have accounted for one-third of all drugs on the world market. In particular, these medicines have been widely used in ocular therapies in the treatment of various diseases, such as age-related macular degeneration, corneal neovascularization, diabetic retinopathy, and retinal vein occlusion. However, the formulation of these biomacromolecules is challenging due to their high molecular weight, complex structure, instability, short half-life, enzymatic degradation, and immunogenicity, which leads to the failure of therapies. Various efforts have been made to overcome the ocular barriers, providing effective delivery of therapeutic proteins, such as altering the protein structure or including it in new delivery systems. These strategies are not only cost-effective and beneficial to patients but have also been shown to allow for fewer drug side effects. In this review, we discuss several factors that affect the design of formulations and the delivery of therapeutic proteins to ocular tissues, such as the use of injectable micro/nanocarriers, hydrogels, implants, iontophoresis, cell-based therapy, and combination techniques. In addition, other approaches are briefly discussed, related to the structural modification of these proteins, improving their bioavailability in the posterior segments of the eye without affecting their stability. Future research should be conducted toward the development of more effective, stable, noninvasive, and cost-effective formulations for the ocular delivery of therapeutic proteins. In addition, more insights into preclinical to clinical translation are needed.

show abstract

“…[63][64][65] Besides, an osmotic pressure gradient can drive the transfer of water from the hypotonic emulsion phase to the hypertonic continuous phase till the emulsions are condensed into MPRs. [66,67] 2) The polymers initially dispersed in immiscible phases and interacted at the liquid-liquid interface through physical factors to form polymer-polymer coacervates, so as to form the stable interface. For instance, polyelectrolytes with opposite charges are complex at the interface through electrostatic attraction.…”

Section: Effects Of Materials On the Interface Characteristics Of Mprsmentioning

confidence: 99%

Microfluidic Particle Reactors: From Interface Characteristics to Cells and Drugs Related Biomedical Applications

Xin

et al. 2022

Adv Materials Inter

View full text Add to dashboard Cite

with advanced functions, [6] can be attributed to two aspects. 1) The exquisite control and manipulation abilities of fluids at a microscale have reached a new height as droplet microfluidic technology is leaping forward. The precisely tunable interface characteristics of emulsion templates, determined by the optimization of fluids composition and interfacial complexity, contribute to the inherent interface properties of MPRs. [7][8][9][10] 2) The introduction of advanced materials expands the interface characteristics of the MPRs. Considerable natural polymers, synthetic polymers, and stimuli-responsive biomaterials have been employed continuously with the development of materials science. As a result, a series of performances possessed by the materials can significantly improve the inherent interface characteristics of the MPRs under a combination of the mentioned advanced materials. [11][12][13][14][15][16] Overall, researchers have stressed the improvement of the development process of interface characteristics and functions (such as substance encapsulation and controlled release) by providing novel technical innovations in every aspect to support biomedical clinical applications related to cells and drugs. Recently, the types, preparation methods, and biomedical applications of MPRs have been systematically presented in several excellent reviews. [3][4][5][8][9][10][17][18][19][20] The thermodynamic properties of liquid-liquid droplet reactors have been analyzed more specifically in some reviews. [7,17] However, the origin of interface characteristics of MPRs, as well as the function and cuttingedge cell-and drug-related biomedical applications determined by the interface characteristics, are deficient in a systematic summary. This review highlights that different emulsion templates endow the inherent interface characteristics of MPRs. Besides, the methods of converting emulsion templates into MPRs are summarized by introducing specific functional biomaterials, followed by the flexible and adjustable interface characteristics expanded by the mentioned materials. Moreover, the biomedical applications related to cells and drugs are analyzed based on the mentioned unique interface characteristics of the MPRs. Furthermore, the existing challenges regarding the current status are presented, and the subsequent development of the MPRs is illustrated from various perspectives (Scheme 1).

show abstract

Poly (Lactic-co-Glycolic Acid) Nanoparticles and Nanoliposomes for Protein Delivery in Targeted Therapy: A Comparative In Vitro Study

Cited by 16 publications

References 45 publications

TB@PLGA Nanoparticles for Photodynamic/Photothermal Combined Cancer Therapy with Single Near-Infrared Irradiation

TB@PLGA Nanoparticles for Photodynamic/Photothermal Combined Cancer Therapy with Single Near-Infrared Irradiation

Ocular Delivery of Therapeutic Proteins: A Review

Microfluidic Particle Reactors: From Interface Characteristics to Cells and Drugs Related Biomedical Applications

Contact Info

Product

Resources

About